Atea Pharmaceuticals, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 4.31 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 345.68M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Details
| Name | Atea Pharmaceuticals, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 55 |
| Founded | 2012 |
| Ipo Date | 2020-10-30 |
| Ceo | Jean-Pierre Sommadossi |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 24.00 |
| Isin | US04683R1068 |
| Cusip | 04683R106 |
| Cik | 0001593899 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Jean-Pierre Sommadossi Ph.D. | Founder, Chairman, Chief Executive Officer and President |
| Andrea J. Corcoran J.D. | Chief Financial Officer, Executive Vice President of Legal and Secretary |
| John F. Vavricka | Chief Commercial Officer |
| Dr. Janet M. J. Hammond M.D., Ph.D. | Chief Development Officer |
| Dr. Maria Arantxa Horga M.D. | Chief Medical Officer |
| Wayne Foster CPA | Executive Vice President of Finance and Chief Accounting Officer |
| Jonae R. Barnes | Senior Vice President of Investor Relations and Corporate Communications |
| Adel Moussa Ph.D. | Executive Vice President of Chemistry |
| Xiao-Jian Zhou Ph.D. | Executive Vice President of Early Stage Development |
| Keith Pietropaolo | Executive Vice President of Clinical Sciences and Project Management |
Contact
| Address | 225 Franklin Street, Suite 2100, Boston, Massachusetts 02110, United States |
| Phone | 857 284 8891 |
| Website | https://ateapharma.com |